The FDA endorsed a ≥2-point reduction on a visual analogue scale for pain as a clinically meaningful endpoint for urcosimod in NCP. NCP is a chronic ocular pain syndrome with no FDA-approved therapies ...
The new pathway has improved communication between primary and secondary care, and reduced waiting times for treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results